Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) announced that recently, KC1086 tablets (“KC1086” for short) independently developed by the company successfully completed the first case of the “KC1086 combined with fluorovisgroup for HR+/HER2- Locally Advanced or Metastatic Breast Cancer Phase II Clinical Study (KC1086-COM-01)”.

Test name: Phase II clinical study to evaluate the safety, efficacy and pharmacokinetic characteristics of KC1086 combined with fluvirizin in patients with positive hormone receptor (HR+) and negative human epidermal growth factor receptor 2 (HER2-) locally advanced or metastatic breast cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.